The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence

Abstract

Manasvi Gupta,1 Shiavax Rao,2 Gaurav Manek,1 Gregg C Fonarow,3 Raktim K Ghosh4 1Department of Internal Medicine, University of Connecticut, Hartford, CT, USA; 2Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USA; 3Department of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA; 4MedStar Heart and Vascular Institute, Union Memorial Hospital, Baltimore, MD, USACorrespondence: Raktim K Ghosh Tel [phone]Fax [phone]Email [email protected]: The burden and cost of heart failure management, primarily in the form of hospitalization in the setting of decompensated heart failure, continue to be some of the biggest clinical challenges in cardiovascular medicine. In recently published randomized controlled trials, including DAPA-HF, sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin was shown to reduce hospitalization from heart failure or mortality associated with cardiovascular causes, when added to existing guideline-directed medical therapy. The American College of Cardiology (ACC) released a Clinical Pathway guideline that recommends the use of dapagliflozin in clinical management of heart failure, with or without diabetes. Furthermore, the results of the DAPA-CKD trial broaden the utility of dapagliflozin as a therapeutic option in patients with advanced kidney disease. In this article, the authors explore the existing evidence on dapagliflozin in heart failure with reduced ejection fraction and highlight the need for further research on uses of dapagliflozin in the world of heart failure.Keywords: dapagliflozin, DAPA-HF, DECLARE-TIMI, DEFINE-HF, HFrEF, DAPA-CKD

Keywords

• dapagliflozin
• dapa-hf
• declare-timi
• define-hf
• hfref
• dapa